19th December 2022
Resistell AG closes its series B first tranche of CHF 8.5m
Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5M from new and existing investors.
3rd October 2022
Join us at BioJapan in Yokohama on 12-14 October 2022
Meet Resistell team at Bio Japan 2022 at Swisstech booth. Learn about World's fastest Antibiotic Susceptibility Test based on the first in class nanomotion technology platform!
13th June 2022
Antimicrobial resistance is one of the top-10 global public health threats facing humanity
To celebrate its 15th anniversary Venture Kick issued movie series about the impact VK alumni have on solving the most pressing global issues. See Resistell in an episode about antibiotic resistance. Thank you for featuring us!
20th April 2022
Resistell initiates a research project funded by an independent grant from Pfizer AG
Resistell, a TOP10 Swiss Start-up addressing the problem of speed in the diagnostics of antibiotic resistance, is pleased to announce they have initiated a research project to assess the applicability of Resistell’s antibiotic susceptibility test (AST) to a novel antibiotic. The project is funded by an independent grant from Pfizer AG.
15th December 2021
Resistell announces completion of clinical pilot performance evaluation study
Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.